{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:58:37Z","timestamp":1781650717506,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Type 2 Diabetes (T2D) is rapidly increasing in Sub-Saharan Africa (SSA), with related health and financial implications. Knowledge of the costs and cost-effectiveness of managing diabetes is needed to increase awareness, improve resource allocation and enhance the use of evidence-based decision-making. Accordingly, this study sought to synthesise and critically review evidence on the costs and cost-effectiveness of managing T2D in Sub-Saharan Africa (SSA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was conducted in multiple databases, including PubMed-Medline, Africa-Wide Information, Web of Science, Cochrane Library, CINAHL, Scopus, and Google Scholar, to identify studies published between January 2010 and December 2023; the searches were updated in June 2024. All cost data were converted to 2024 United States dollars (US$) using appropriate inflation adjustments and exchange rates. The review protocol was registered with PROSPERO (CRD42022300580).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The search yielded 4137 unique abstracts, and 18 studies were included for review, most originating from Nigeria. Most studies assessed costs from a provider perspective, focusing on direct medical costs (e.g., outpatient consultations, medications, diagnostic and monitoring tests, and follow-up care). Reported costs of T2D management were substantial across settings. Annual costs ranged from US$337.50 for basic medical care of uncomplicated T2D to US$2330.74 in total provider cost per patient. The highest burden was reported among individuals in the low-income quantile. Only five studies assessed cost-effectiveness, most using modelling and simulation approaches. T2D management programmes can be cost-effective, but the evidence remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This review identified substantial variation in methods, perspectives, and cost components across T2D cost studies in SSA, which limits direct comparability. Improving methodological transparency and reporting, alongside addressing data-collection gaps, would strengthen the evidence base. Further context-specific economic evaluations, particularly those incorporating affordability, implementation feasibility, and budget impact, are needed to support priority setting and resource allocation for T2D management in SSA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13561-026-00777-1","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:08:18Z","timestamp":1776852498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Costs and cost-effectiveness of type 2 diabetes management in Sub-Saharan Africa: a systematic review"],"prefix":"10.1186","volume":"16","author":[{"given":"Assegid","family":"Hellebo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre P.","family":"Kengne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olufunke A.","family":"Alaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"issue":"8","key":"777_CR1","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1093\/heapol\/czu106","volume":"30","author":"W Dukpa","year":"2015","unstructured":"Dukpa W, Teerawattananon Y, Rattanavipapong W, Srinonprasert V, Tongsri W, Kingkaew P, Yothasamut J, Wangchuk D, Dorji T, Wangmo K. Are diabetes and hypertension screening worthwhile in resource-limited settings? An economic evaluation based on a pilot of a Package of Essential Non-communicable disease interventions in Bhutan. Health Policy Plan. 2015;30(8):1032\u201343.","journal-title":"Health Policy Plan"},{"key":"777_CR2","doi-asserted-by":"crossref","unstructured":"Elias MA, Pati MK, Aivalli P, Srinath B, Munegowda C, Shroff ZC, Bigdeli M, Srinivas PN. Preparedness for delivering non-communicable disease services in primary care: access to medicines for diabetes and hypertension in a district in south India. BMJ Glob Health. 2017;2(Suppl 3):e000519.","DOI":"10.1136\/bmjgh-2017-000519"},{"key":"777_CR3","unstructured":"International Diabetes Federation (IDF). Diabetes Atlas. 9th ed. Brussels: International Diabetes Federation; 2019. Available from: https:\/\/diabetesatlas.org."},{"issue":"4","key":"777_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5001\/omj.2012.68","volume":"27","author":"AB Olokoba","year":"2012","unstructured":"Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med J. 2012;27(4):269\u201373.","journal-title":"Oman Med J"},{"key":"777_CR5","unstructured":"International Diabetes Federation (IDF). Diabetes facts & figures. Brussels; 2021. Available from: IDF Diabetes Facts and Figures."},{"issue":"9","key":"777_CR6","doi-asserted-by":"publisher","first-page":"107671","DOI":"10.1016\/j.jdiacomp.2020.107671","volume":"34","author":"AE Caballero","year":"2020","unstructured":"Caballero AE, Ceriello A, Misra A, Aschner P, McDonnell ME, Hassanein M, Ji L, Mbanya JC, Fonseca VA. COVID-19 in people living with diabetes: An international consensus. J Diabetes Complications. 2020;34(9):107671.","journal-title":"J Diabetes Complications"},{"issue":"2","key":"777_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.diabres.2013.11.006","volume":"103","author":"N Peer","year":"2014","unstructured":"Peer N, Kengne AP, Motala AA, Mbanya JC. Diabetes in the Africa Region: An update. Diabetes Res Clin Pract. 2014;103(2):197\u2013205.","journal-title":"Diabetes Res Clin Pract"},{"key":"777_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40842-019-0077-8","volume":"5","author":"D Kibirige","year":"2019","unstructured":"Kibirige D, Lumu W, Jones AG, Smeeth L, Hattersley AT, Nyirenda MJ. Understanding the manifestation of diabetes in sub\u2013Saharan Africa to inform therapeutic approaches and preventive strategies: a narrative review. Clin Diabetes Endocrinol. 2019;5:2.","journal-title":"Clin Diabetes Endocrinol"},{"issue":"2","key":"777_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s13300-013-0034-y","volume":"4","author":"LE Garc\u00eda-P\u00e9rez","year":"2013","unstructured":"Garc\u00eda-P\u00e9rez LE, Alvarez M, Dilla T, Gil-Guill\u00e9n V, Orozco-Beltr\u00e1n D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175\u201394.","journal-title":"Diabetes Ther"},{"issue":"2","key":"777_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.metabol.2014.10.018","volume":"64","author":"L Chen","year":"2015","unstructured":"Chen L, Pei JH, Kuang J, Chen HM, Chen Z, Li ZW, Yang HZ. Effect of lifestyle intervention in patients with type 2 diabetes: a meta-analysis. Metabolism. 2015;64(2):338\u201347.","journal-title":"Metabolism"},{"key":"777_CR11","unstructured":"World Health Organisation, W. Diabetes overview Online. Defining Diabetes. 2020a. Retrieved September 19September 19 2022 from https:\/\/www.who.int\/health-topics\/diabetes#tab=tab_1."},{"key":"777_CR12","doi-asserted-by":"crossref","unstructured":"Turner HC, Archer RA, Downey LE, Isaranuwatchai W, Chalkidou K, Jit M, Teerawattananon Y. An Introduction to the Main Types of Economic Evaluations Used for Informing Priority Setting and Resource Allocation in Healthcare: Key Features, Uses, and Limitations. Front Public Health. 2021;9:722927.","DOI":"10.3389\/fpubh.2021.722927"},{"key":"777_CR13","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1186\/s12913-018-3450-x","volume":"18","author":"K Edmunds","year":"2018","unstructured":"Edmunds K, Ling R, Shakeshaft A, et al. A systematic review of economic evaluations of interventions for high-risk young people. BMC Health Serv Res. 2018;18:660.","journal-title":"BMC Health Serv Res"},{"key":"777_CR14","volume-title":"Macroeconomics and health: investing in health for economic development","author":"WHO, W. H. O","year":"2001","unstructured":"WHO, W. H. O. Macroeconomics and health: investing in health for economic development. Geneva: World Health Organisation; 2001."},{"issue":"7","key":"777_CR15","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jval.2017.12.016","volume":"21","author":"AA Leech","year":"2018","unstructured":"Leech AA, Kim DD, Cohen JT, Neumann PJ. Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. Value Health. 2018;21(7):759\u201361.","journal-title":"Value Health"},{"issue":"01","key":"777_CR16","first-page":"S1","volume":"127","author":"A Petersmann","year":"2019","unstructured":"Petersmann A, Muller-Wieland D, Muller UA, Landgraf R, Nauck M, Freckmann G, Heinemann L, Schleicher E. Definition, Classification and Diagnosis of Diabetes Mellitus. Exp Clin Endocrinol Diabetes. 2019;127(01):S1\u20137.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"777_CR17","unstructured":"Abdulganiyu G, Fola T. What is the cost of illness of type II diabetes mellitus in a developing economy? Int J Pharm Pharm Sci. 2014;6(Suppl 2):927\u201331."},{"issue":"1","key":"777_CR18","first-page":"79","volume":"44","author":"AE Ipingbemi","year":"2015","unstructured":"Ipingbemi AE, Erhun WO. Cost implications of treating diabetes mellitus in a secondary healthcare facility in Ibadan. Afr J Med Med Sci. 2015;44(1):79\u201387.","journal-title":"Afr J Med Med Sci"},{"key":"777_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Moher D. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103\u201312. PMID: 33577987.","journal-title":"J Clin Epidemiol"},{"key":"777_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"H Mourad Ouzzani","year":"2016","unstructured":"Mourad Ouzzani H, Hammady. Zbys Fedorowicz, and Ahmed Elmagarmid. Rayyan - a web and mobile app for systematic reviews. Syst Reviews. 2016;5:210.","journal-title":"Syst Reviews"},{"key":"777_CR21","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions. Version 6.3, updated February 2022. London: Cochrane; 2022."},{"key":"777_CR22","unstructured":"OANDA, Corporation. Currency converter New York: OANDA Corporation. Available from: https:\/\/www.oanda.com\/currency-converter\/en\/?from=EUR&to=USD&amount=1. [cited 2024 March 24March 24]."},{"issue":"2","key":"777_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4314\/mmj.v27i2.7","volume":"27","author":"J Fadare","year":"2015","unstructured":"Fadare J, Olamoyegun M, Gbadegesin BA. Medication adherence and direct treatment cost among diabetes patients attending a tertiary healthcare facility in Ogbomosho, Nigeria. Malawi Med J. 2015;27(2):65\u201370.","journal-title":"Malawi Med J"},{"key":"777_CR24","doi-asserted-by":"crossref","unstructured":"Ipingbemi AE, Erhun WO, Adisa R. Pharmacist-led intervention in treatment non-adherence and associated direct costs of management among ambulatory patients with type 2 diabetes in southwestern Nigeria. BMC Health Serv Res. 2021;21(1):1000.","DOI":"10.1186\/s12913-021-06979-z"},{"key":"777_CR25","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s13104-015-1489-x","volume":"8","author":"IL Okoronkwo","year":"2015","unstructured":"Okoronkwo IL, Ekpemiro JN, Okwor EU, Okpala PU, Adeyemo FO. Economic burden and catastrophic cost among people living with type2 diabetes mellitus attending a tertiary health institution in the south-east zone, Nigeria. BMC Res Notes. 2015;8:527.","journal-title":"BMC Res Notes"},{"issue":"1","key":"777_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.respe.2016.06.334","volume":"65","author":"K Alouki","year":"2017","unstructured":"Alouki K, Delisle H, Besan\u00e7on S. Analyse des co\u00fbts m\u00e9dicaux directs des soins du diab\u00e8te de type 2 au Mali [Analysis of direct medical costs of type 2 diabetes in Mali]. Rev Epidemiol Sante Publique. 2017;65(1):41\u201351. French.","journal-title":"Rev Epidemiol Sante Publique"},{"key":"777_CR27","doi-asserted-by":"crossref","unstructured":"Bermudez-Tamayo C, Besan\u00e7on S, Johri M, Assa S, Brown JB, Ramaiya K. Direct and indirect costs of diabetes mellitus in Mali: a case-control study. PLoS One. 2017;12(5):e0176128.","DOI":"10.1371\/journal.pone.0176128"},{"issue":"10","key":"777_CR28","doi-asserted-by":"publisher","first-page":"e0276702","DOI":"10.1371\/journal.pone.0276702","volume":"17","author":"L Masis","year":"2022","unstructured":"Masis L, Kanya L, Kiogora J, Kiapi L, Tulloch C, Alani AH. Estimating treatment costs for uncomplicated diabetes at a hospital serving refugees in Kenya. PLoS ONE. 2022;17(10):e0276702.","journal-title":"PLoS ONE"},{"key":"777_CR29","doi-asserted-by":"crossref","unstructured":"Obakiro SB, Kiyimba K, Napyo A, Kanyike AM, Mayoka WJ, Nnassozi AG, Aguti B, Akech GM, Waako JP. Appropriateness and affordability of prescriptions to diabetic patients attending a tertiary hospital in Eastern Uganda: a retrospective cross-sectional study. PLoS One. 2021;16(1):e0245036.","DOI":"10.1371\/journal.pone.0245036"},{"key":"777_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.vhri.2015.08.005","volume":"7","author":"EA Quaye","year":"2015","unstructured":"Quaye EA, Amporful EO, Akweongo P, Aikins MK. Analysis of the Financial Cost of Diabetes Mellitus in Four Cocoa Clinics of Ghana. Value Health Reg Issues. 2015;7:49\u201353.","journal-title":"Value Health Reg Issues"},{"key":"777_CR31","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/bmjinnov-2018-000278","volume":"4","author":"M Wargny","year":"2018","unstructured":"Wargny M, Kleinebreil L, Diop SN, Ndour-Mbaye M, Ba M, Balkau B. Simon D. SMS-based intervention in type 2 diabetes: a clinical trial in Senegal. BMJ Innovations. 2018;4:142\u20136.","journal-title":"BMJ Innovations"},{"issue":"1","key":"777_CR32","doi-asserted-by":"publisher","first-page":"1636611","DOI":"10.1080\/16549716.2019.1636611","volume":"12","author":"A Erzse","year":"2019","unstructured":"Erzse A, Stacey N, Chola L, Tugendhaft A, Freeman M, Hofman K. The direct medical cost of type 2 diabetes mellitus in South Africa: a cost of illness study. Glob Health Action. 2019;12(1):1636611.","journal-title":"Glob Health Action"},{"issue":"7","key":"777_CR33","doi-asserted-by":"publisher","first-page":"635","DOI":"10.7196\/SAMJ.2021.v111i7.15169","volume":"111","author":"AM Opperman","year":"2021","unstructured":"Opperman AM, De Klerk M. A total cost perspective of type 1 and 2 diabetes mellitus in two South African medical schemes servicing the public healthcare sector. S Afr Med J. 2021;111(7):635\u201341.","journal-title":"S Afr Med J"},{"issue":"1","key":"777_CR34","doi-asserted-by":"publisher","first-page":"238146832110057","DOI":"10.1177\/23814683211005771","volume":"6","author":"M Bekele","year":"2021","unstructured":"Bekele M, Norheim OF, Hailu A. Cost-Effectiveness of Saxagliptin Compared With Glibenclamide as a Second-Line Therapy Added to Metformin for Type 2 Diabetes Mellitus in Ethiopia. MDM Policy Pract. 2021;6(1):23814683211005771.","journal-title":"MDM Policy Pract"},{"key":"777_CR35","doi-asserted-by":"crossref","unstructured":"Juarez-Garcia A, Casalvolone D, Qatami L, Bergenheim K, Donato BMK. Cost-Effectiveness of Saxagliptin in Type 2 Diabetes in South Africa. Research Poster Presentation - Session Iv Disease-Specific Studies: Diabetes\/Endocrine Disorders \u2013 Cost Study| 15. 2012(4):Pa180.","DOI":"10.1016\/j.jval.2012.03.974"},{"issue":"5","key":"777_CR36","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.pec.2015.01.005","volume":"98","author":"R Mash","year":"2015","unstructured":"Mash R, Kroukamp R, Gaziano T, Levitt N. Cost-effectiveness of a diabetes group education program delivered by health promoters with a guiding style in underserved communities in Cape Town, South Africa. Patient Educ Couns. 2015;98(5):622\u20136.","journal-title":"Patient Educ Couns"},{"key":"777_CR37","doi-asserted-by":"crossref","unstructured":"Volmink HC, Bertram MY, Jina R, Wade AN, Hofman KJ. Applying a private sector capitation model to the management of type 2 diabetes in the South African public sector: a cost-effectiveness analysis. BMC Health Serv Res. 2014;14:444.","DOI":"10.1186\/1472-6963-14-444"},{"key":"777_CR38","doi-asserted-by":"crossref","unstructured":"Adibe MO, Aguwa CN, Ukwe CV. Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes. Value Health Reg Issues. 2013;2(2):189\u201398.","DOI":"10.1016\/j.vhri.2013.06.009"},{"key":"777_CR39","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s13104-015-1489-x","volume":"8","author":"IL Okoronkwo","year":"2015","unstructured":"Okoronkwo IL, Ekpemiro JN, Okwor EU, Okpala PU, Adeyemo FO. Economic burden and catastrophic cost among people living with type2 diabetes mellitus attending a tertiary health institution in south-east zone, Nigeria. BMC Res Notes. 2015;8:527.","journal-title":"BMC Res Notes"},{"key":"777_CR40","doi-asserted-by":"crossref","unstructured":"Lee S, Ryu KS, Kang HYJ, You NY, Choi KS, Hwangbo Y, Lee JW, Cha HS. Risk factors of undiagnosed diabetes mellitus among Korean adults: a national cross-sectional study using the KNHANES data. Int J Environ Res Public Health. 2021;18(3):1195.","DOI":"10.3390\/ijerph18031195"},{"issue":"10","key":"777_CR41","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103.","journal-title":"JAMA"}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13561-026-00777-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-026-00777-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-026-00777-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:33:21Z","timestamp":1781649201000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13561-026-00777-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["777"],"URL":"https:\/\/doi.org\/10.1186\/s13561-026-00777-1","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed for the last version to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}